Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 149-164 , June 2008

Polymorphisms of cytokine and innate immunity genes and GVHD

  • A.M. Dickinson (Professor of Marrow Transplant Biology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 191 282 4259; Fax: +44 191 222 6794.

References 

  1. Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplantation. 1995;15:99–104
  2. Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83:2360–2367
  3. Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning–an alternative target for modulation of acute GVHD and complications following allogeneic bone marrow transplantation?. Leukemia and lymphoma. 1997;25:217–224
  4. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941–3946
  5. Middleton PG, Taylor PRA, Jackson G, et al. Cytokine Gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943–3948
  6. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clinical and Experimental Immunology. 1993;92:14–18
  7. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. European Journal of Immunology. 1993;23:224–231
  8. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation. 1995;60:1113–1117
  9. Nedospasov SA, Udalova IA, Kuprash DV, et al. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. Journal of Immunology (Baltimore, Md. : 1950). 1991;147:1053–1059
  10. Udalova IA, Nedospasov SA, Webb GC, et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993;16:180–186
  11. Holzinger I, de Baey A, Messer G, et al. Cloning and genomic characterization of LST1: a new gene in the human TNF region. Immunogenetics. 1995;42:315–322
  12. Turner D, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation. 1997;64:776–779
  13. Pociot F, Molvig J, Wogensen L, et al. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scandinavian Journal of Immunology. 1991;33:37–49
  14. Keen LJ, DeFor TE, Bidwell JL, et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood. 2004;103:3599–3602
  15. Nordlander A, Uzunel M, Mattsson J, et al. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. British Journal of Haematology. 2002;119:1133–1336
  16. Bettens F, Passweg J, Gratwohl A, et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation. 2006;81:1261–1267
  17. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2003;32:617–622
  18. Tambur AR, Yaniv I, Stein J, et al. Cytokine gene polymorphism in patients with graft-versus-host disease. Transplantation Proceedings. 2001;33:502–503
  19. Rocha V, Franco RF, Porcher R, et al. Host defence and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplant. Blood. 2002;100:3908–3918
  20. Mullighan CG, Bardy PG. Advances in the genomics of allogeneic haemopoietic stem cell transplantation. Drug Development Research. 2004;62:273–292
  21. Ishikawa Y, Kashiwase K, Akaza K, et al. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation. Bone Marrow Transplantation. 2002;29:569–575
  22. Stark GL, Dickinson AM, Jackson GH, et al. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation. 2003;76:1742–1749
  23. Cullup H, Stark G. Interleukin-1 polymorphisms and graft versus host disease. Leukemia and lymphoma. 2005;46:517–523
  24. Cullup H, Dickinson AM, Jackson GH, et al. Donor interleukin-1 receptor antagonist genotype associated with acute graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic transplants. British Journal of Haematology. 2001;113:807–813
  25. Cullup H, Dickinson AM, Cavet J, et al. Polymorphisms of IL-1alpha constitute independent risk factors for chronic graft versus host disease following allogeneic bone marrow transplantation. British Journal of Haematology. 2003;122:778–787
  26. MacMillan ML, Radloff GA, DeFor TE, et al. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. British Journal of Haematology. 2003;121:597–604
  27. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994;84:1342–1348
  28. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002;100:3479–3482
  29. Ferrari SL, Ahn-Luong L, Garnero P, et al. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. 2003;88:255–259
  30. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. The Journal of Biological Chemistry. 2000;275:18138–18144
  31. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of Clinical Investigation. 1998;102:1369–1376
  32. Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Human Immunology. 2005;66:700–710
  33. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–1600
  34. Socié G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72:699–706
  35. Janeway CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunology Today. 1992;13:11–16
  36. Janeway CA, Medzhitov R. Innate immune recognition. Annual Review of Immunology. 2002;20:197–216
  37. Matzinger P. Tolerance, danger, and the extended family. Annual Review of Immunology. 1994;12:991–1045
  38. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature immunology. 2004;5:987–995
  39. Takeda K, Akira S. Toll-like receptors in innate immunity. International Immunology. 2005;17:1–14
  40. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends in Immunology. 2005;26:447–454
  41. Inohara , Chamaillard , McDonald C, et al. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annual Review of Biochemistry. 2005;74:355–383
  42. Ku CL, Yang K, Bustamante J, et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunological Reviews. 2005;203:10–20
  43. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734
  44. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nature Immunology. 2004;5:800–808
  45. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nature Reviews. Immunology. 2003;3:371–382
  46. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell. 2002;10:417–426
  47. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Current Opinion in Immunology. 2007;19:39–45
  48. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nature Immunology. 2001;2:947–950
  49. Andonegui G, Bonder CS, Green F, et al. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. The Journal of Clinical Investigation. 2003;111:1011–1020
  50. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801
  51. Shen XD, Ke B, Zhai Y, et al. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. American Journal of Transplantation. 2005;5:1793–1800
  52. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. Journal of Immunology (Baltimore, Md. : 1950). 2004;173:7115–7119
  53. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. Journal of Immunology (Baltimore, Md. : 1950). 2000;164:558–561
  54. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. The Journal of Biological Chemistry. 2002;277:15107–15112
  55. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. The Journal of Biological Chemistry. 2002;277:20847–20853
  56. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (Augusta, Ga.). 2006;26:174–179
  57. Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation. 2006;81:247–254
  58. Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2001;7:384–387
  59. Kesh S, Mensah NY, Peterlongo P, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Annals of the New York Academy of Sciences. 2005;1062:95–103
  60. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. American Journal of Respiratory and Critical Care Medicine. 2003;168:628–632
  61. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. American Journal of Respiratory and Critical Care Medicine. 2005;171:780–785
  62. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney International. 2005;67:2454–2461
  63. Walker WE, Nasr IW, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. Journal of Immunology (Baltimore, Md. : 1950). 2006;177:5307–5316
  64. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–1036
  65. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nature Medicine. 2000;6:435–442
  66. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. International Immunology. 2000;12:1539–1546
  67. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GVHD following allogeneic stem cell transplantation. Blood. 2004;104:889–894
  68. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood. 2006;107:4189–4193
  69. Granell M, Urbano-Ispizua A, Arostegui JI, et al. Detrimental effect of NOD2/CARD15 polymorphisms in T-cell depleted allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37:S79;P431
  70. Hildebrandt GC, Granell M, Urbano-Ispizua A, et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2008;14:67–74
  71. MacMillan ML, Radloff GA, Kiffmeyer WR, et al. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation. 2003;76:1758–1762
  72. Yang YG, Wang H, Asavaroengchai W, et al. Role of Interferon-gamma in GVHD and GvL. Cellular and Molecular Immunology. 2005;2:323–329
  73. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, et al. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2005;90:425–426
  74. Mlynarczewska A, Wysoczanska B, Karabon L, et al. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34:339–344
  75. Brok HP, Heidt PJ, van der Meide PH, et al. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. Journal of Immunology (Baltimore, Md. : 1950). 1993;151:6451–6459
  76. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics. 1997;24:1–8
  77. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology (Baltimore, Md.). 1999;30:526–530
  78. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. The New England Journal of Medicine. 2003;349:2201–2210
  79. Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood. 2005;106:3995–4001
  80. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2005;36:1089–1095
  81. Takahashi H, Furukawa T, Hashimoto S, et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2000;26:1317–1323
  82. Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood. 2005;106:2206–2214
  83. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta 1. Human Molecular Genetics. 1999;8:93–97
  84. Leffell MS, Vogelsang GB, Lucas DP, et al. Association between TGF-beta expression and severe GVHD in allogeneic bone marrow transplantation. Transplantation Proceedings. 2001;33:485–486
  85. Hattori H, Matsuzaki A, Suminoe A, et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplantation. 2002;30:665–671
  86. Jordan WJ, Brookes PA, Szydlo RM, et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood. 2004;103:717–724
  87. Joshi BH, Hogaboam C, Dover P, et al. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitamins and Hormones. 2006;74:479–504
  88. Ohashi J, Naka I, Patarapotikul J, et al. A single-nucleotide substitution from C to T at position -1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes and Immunity. 2003;4:528–531
  89. Steck AK, Bugawan TL, Valdes AM, et al. Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes. 2005;54:2482–2486
  90. Yigit B, Bozkurt N, Berber I, et al. Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival. Cell Biochemistry and Function. 2006;
  91. Bogunia-Kubik K, Duda D, Suchnicki K, et al. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1628–1634
  92. Welniak LA, Wang Z, Sun K, et al. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Experimental Hematology. 2004;32:318–324
  93. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. Journal of Immunology (Baltimore, Md. : 1950). 2004;173:845–854
  94. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106:3322–3330
  95. Faaij CM, Lankester AC, Spierings E, et al. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. British Journal of Haematology. 2006;133:538–549
  96. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11:280–287
  97. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology. 2003;31:897–902
  98. Varona R, Cadenas V, Gomez L, et al. CCR6 regulates CD4+T-cell-mediated acute graft-versus-host disease responses. Blood. 2005;106:18–26
  99. Loeffler J, Steffens M, Arlt EM, et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. Journal of Clinical Microbiology. 2006;44:1847–1850
  100. Maeda Y, Reddy P, Lowler KP, et al. Critical role of host T gamma delta cells in experimental acute graft-versus-host disease. Blood. 2005;106:749–755
  101. Lue H, Kleemann R, Calandra T, et al. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes and Infection/Institut Pasteur. 2002;4:449–460
  102. Choi SW, Hildebrandt GC, Olkiewicz KM, et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood. 2007;110:3447–3455
  103. Yang J, Qiao HL, Dong ZM. Polymorphisms of IL-13 and IL-4-IL-13-SNPs in patients with penicillin allergies. European Journal of Clinical Pharmacology. 2005;61:803–809
  104. Cardoso SM, DeFor TE, Tilley LA, et al. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. British Journal of Haematology. 2004;126:704–710
  105. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003;101:2877–2885
  106. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 2004;77:587–596
  107. Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37:485–491
  108. Middleton PG, Cullup H, Cavet J, et al. Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplantation. 2003;32:41–47
  109. Middleton PG, Cullup H, Dickinson AM, et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2002;30:223–228
  110. Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome?. Expert Reviews in Molecular Medicine. 2007;9:1–19
  111. Hansen JA, Petersdorf EW, Lin MT, et-al. Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. Immunologic research; in press.

PII: S1521-6926(08)00035-2

doi: 10.1016/j.beha.2008.03.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 149-164 , June 2008

Article Tools